Workflow
乌龙制药(URGN)
icon
搜索文档
UroGen Pharma(URGN) - 2022 Q2 - Earnings Call Transcript
2022-08-12 02:48
Urogen Pharma Ltd (NASDAQ:URGN) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Jeffrey Bova - Chief Commercial Officer Dong Kim - CFO Conference Call Participants Christopher Howerton - Jefferies Raghuram Selvaraju - H.C. Wainwright & Co. Boris Peaker - Cowen and Company Matthew Kaplan - Ladenburg Thalmann & Co. Leland Gershell - Oppenheimer Operator ...
UroGen Pharma(URGN) - 2022 Q1 - Earnings Call Transcript
2022-05-11 04:35
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Don Kim - CFO Conference Call Participants Ram Selvaraju - H.C. Wainwright Boris Peaker - Cowen Chris Howerton - Jefferies Matt Kaplan - Ladenburg Thalmann Leland Gershell - Oppenheimer Anita Dushyanth - Berenberg Capital Operator Good morning, ladies ...
UroGen Pharma(URGN) - 2021 Q4 - Earnings Call Transcript
2022-03-22 02:43
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2021 Earnings Conference Call March 21, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director of Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Boris Peaker - Cowen Christopher Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Operator Good morning, ...
Urogen Pharma (URGN) Investor Presentation - Slideshow
2021-11-20 02:58
NOVEMBER 2021 UROGEN PHARMA Forward Looking Statements 2 This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the potential of UroGen's proprietary RTGel™ technolog ...
UroGen Pharma(URGN) - 2021 Q3 - Earnings Call Transcript
2021-11-16 02:19
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2021 Earnings Conference Call November 15, 2021 10:00 AM ET Company Participants Lee Roth - IR Liz Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - CFO Conference Call Participants Chris Howerton - Jefferies Paul Choi - Goldman Sachs Matt Kaplan - Ladenburg Thalmann Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, and thank you for standing by. And welcome to UroGen Pharma' ...
UroGen Pharma(URGN) - 2021 Q2 - Earnings Call Transcript
2021-08-07 19:50
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants Sara Sherman - Head of Investor Relations Liz Barrett - President and CEO Jeff Bova - Chief Commercial Officer Mark Schoenberg - Chief Medical Officer Molly Henderson - CFO Conference Call Participants Leland Gershell - Oppenheimer Chris Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Paul Choi - Goldman Sachs Operator Good morning, ladies and gentlemen, and ...
UroGen Pharma (URGN) Presents At HealthVirtual Conference - Slideshow
2021-07-17 05:52
UROGEN PHARMA LADENBURG THALMANN HEALTHCARE CONFERENCE JULY 14, 2021 2 Forward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the potential ...
UroGen Pharma(URGN) - 2021 Q1 - Earnings Call Transcript
2021-05-14 01:52
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Â Company Participants Lee Roth - Burns McClellan Liz Barrett - President and CEO Jeff Bova - Chief Commercial Officer Mark Schoenberg - Chief Medical Officer Molly Henderson - CFO Conference Call Participants Hannah Adeoye - JPMorgan Chris Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Paul Choi - Goldman Sachs Leland Gershell - Oppenheimer Operator Good morning, ladies and gentl ...
UroGen Pharma(URGN) - 2020 Q4 - Earnings Call Transcript
2021-03-19 01:54
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2020 Results Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Sara Sherman - Head, Investor Relations Liz Barrett - President and CEO Dr. Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Chris Howerton - Jefferies Derek Archila - Stifel Hannah Adeoye - J.P. Morgan Matt Kaplan - Ladenburg Thalmann Paul Choi - Goldman Sachs Operator Good morning, ladies ...
Urogen Pharma (URGN) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow
2021-03-18 01:56
UROGEN PHARMA OPPENHEIMER 31ST ANNUAL HEALTHCARE CONFERENCE MARCH 16, 2021 2 Forward Looking Statements This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the pot ...